amnog Benefit assessment

AMNOG Benefit assessment

We analyzed the outcomes of previous AMNOG BENEFIT ASSESSMENTS to enable our pharma clients to improve their Market Access and Reimbursement planning.

The benefit assessment of pharmaceuticals in accordance with the German Social Code, Book Five (SGB V), section 35a

This page compiles information on the benefit assessment of pharmaceuticals
in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG).

presented by

About Advisors in Healthcare

Market Access & Reimbursement 

  • Market Access Pre-Dossier Strategy Development
  • Market Access Dossier Development
  • Dossier Process and Project Management
  • Preparation for Hearings and Negotiation Support 
  • Post-Dossier Strategy and Payor Contracting

 

Market Access Interim Management

Due to their extensive experience in operative management and their brief adjustment periods, our seasoned Market Access experts are extremely well suited for Interim Management assignments.

  • Market Access
  • HEOR
  • Pricing & Reimbursement
  • Biostatistics
    Looking for Support?

    "Knowing about the outcomes of previous AMNOG evaluations and price negotiations is an invaluable basis for your Market Access planning"

    Dr. Roman Rittweger

    Founder and Shareholder

    Roman Rittweger Advisors in Healthcare

    Analysis Benefit Assessment

    With the AMNOG BENEFIT ASSESSMENT analysis we developed a tool where you can see the outcomes of the benefit assessment at a glance.

    We analyzed and compared the additional benefit that was recommended by the Institute for Quality and Efficiency in Health Care (IQWiG) and then assessed by the Federal Joint Committee (G-BA) with the expectations of the manufacturers.

    This section is based on subpopulations and does not include orphan drugs.

    Please find here our analysis focusing on

    You can request a download of the entire analysis free of charge.

    Free Download

    "We have developed the AMNOG BENEFIT ASSESSMENT analysis in order to enable you to access a summary of the available information at a single mouseclick"

    Anne Kuhbier 

    Managing Director

    Roman Rittweger Advisors in Healthcare

    Analysis Orphan Drugs

    Orphan drugs have a special status in the early benefit assessment because their additional benefit is already proven with the EMA approval (SGB V, §35a, paragraph 1, sentence 10).

    That is why we included a separate overview with the additional benefits only for orphan drugs.

    You can  also find an analysis focusing on the different  therapeutic areas defined by the Federal Joint Committee (G-BA) below.

    You can request a download of the entire analysis free of charge.

    Free Download

    Therapeutic Areas

    BLOOD & BLOOD FORMING ORGANS

    CARDIOVASCULAR

    DIGESTIVE SYSTEM

    EYE

    GENITOURINARY

    INFECTIOUS

    MENTAL

    METABOLIC

    MUSCULO-SKELETAL

    NERVOUS SYSTEM

    ONCOLOGICAL

    RESPIRATORY

    SKIN

    OTHERS

    Free Download

    Request Your Free Download

    Please fill in the form to get the entire analysis free of charge

    CONTACT US

    Roman Rittweger 
    Advisors in Healthcare GmbH

    Maximilianstrasse 31
    80539 Munich

    +49 89 212 69 33 0

    office@advisorsinhealthcare.com

    MEET US

    TALK TO US

    IMPRINT

    General Terms & Conditions

    Disclaimer

    © Roman Rittweger Advisors in Healthcare